DUBLIN, May 11, 2015 /PRNewswire/ --
- First quarter revenues of $714 million
- First quarter reported $0.85 diluted (GAAP) EPS from continuing operations and $1.17 adjusted diluted EPS from continuing operations
- U.S. Branded Pharmaceuticals first quarter revenues increase of 21 percent primarily attributable to the acquisition of Auxilium Pharmaceuticals
- U.S. Generic Pharmaceuticals continues strong growth in first quarter with 68 percent revenue increase overfirst quarter 2014
- International Pharmaceuticals first quarter results on-track and aligned with Company expectations
- Affirms revenue guidance from continuing operations and raises adjusted diluted EPS from continuing operations guidance for full year 2015
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today reported first quarter 2015 financial results, including:
- Revenues of $714 million, a 52 percent increase compared to first quarter 2014 revenues of $471 million, including new product revenue from 2014 and 2015 strategic M&A transactions.
- Reported income from continuing operations of $150 million compared to a first quarter 2014 reported loss from continuing operations of $47 million.
- Adjusted income from continuing operations of $207 million, a 91 percent increase compared to first quarter 2014 adjusted income from continuing operations of $108 million.
Reported diluted EPS from continuing operations of $0.85 compared to first quarter 2014 reported loss per share from continuing operations of $0.37.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
